Login / Signup

Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.

Mashari AlzahraniCarol StoberMichelle LiuArif AwanTerry L NgGregory PondBader AlshamsanLisa VandermeerMark Clemons
Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
The risk for SSEs was greatest in the first year after diagnosis of bone metastasis. Studies evaluating de-escalation and even stopping of BMAs with longer-term use may therefore be warranted.
Keyphrases
  • bone mineral density
  • preterm infants
  • prostate cancer
  • gestational age
  • soft tissue
  • bone loss
  • bone regeneration
  • randomized controlled trial
  • clinical trial
  • body composition
  • drug induced